Publications
Lee HJ, Boscardin J, Walter LC, Smith AK, Cohen HJ, Giri S, Williams GR, Presley CJ, Singhal S, Huang LW, Velazquez AI, Gubens MA, Blakely CM, Mulvey CK, Cheng ML, Sakoda LC, Kushi LH, Quesenberry C, Liu R, Fleszar-Pavlovic S, Eskandar C, Cutler E, Mercurio AM, Wong ML. Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. The oncologist. 2024. PMID: 39657913
Lee HJ, Boscardin J, Walter LC, Smith AK, Cohen HJ, Giri S, Williams GR, Presley CJ, Singhal S, Huang LW, Velazquez AI, Gubens MA, Blakely CM, Mulvey CK, Cheng ML, Sakoda LC, Kushi LH, Quesenberry C, Liu R, Fleszar-Pavlovic S, Eskandar C, Cutler E, Mercurio AM, Wong ML. Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. The oncologist. 2024. PMID: 39657913
Lee HJ, Boscardin J, Walter LC, Smith AK, Cohen HJ, Giri S, Williams GR, Presley CJ, Singhal S, Huang LW, Velazquez AI, Gubens MA, Blakely CM, Mulvey CK, Cheng ML, Sakoda LC, Kushi LH, Quesenberry C, Liu R, Fleszar-Pavlovic S, Eskandar C, Cutler E, Mercurio AM, Wong ML. Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. The oncologist. 2024. PMID: 39657913
Turnham RE, Pitea A, Jang GM, Xu Z, Lim HC, Choi AL, Von Dollen J, Levin RS, Webber JT, McCarthy E, Hu J, Li X, Che L, Singh A, Yoon A, Chan G, Kelley RK, Swaney DL, Zhang W, Bandyopadhyay S, Theis FJ, Eckhardt M, Chen X, Shokat KM, Ideker T, Krogan NJ, Gordan JD. HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research. 2024. PMID: 39652575
Turnham RE, Pitea A, Jang GM, Xu Z, Lim HC, Choi AL, Von Dollen J, Levin RS, Webber JT, McCarthy E, Hu J, Li X, Che L, Singh A, Yoon A, Chan G, Kelley RK, Swaney DL, Zhang W, Bandyopadhyay S, Theis FJ, Eckhardt M, Chen X, Shokat KM, Ideker T, Krogan NJ, Gordan JD. HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research. 2024. PMID: 39652575
Turnham RE, Pitea A, Jang GM, Xu Z, Lim HC, Choi AL, Von Dollen J, Levin RS, Webber JT, McCarthy E, Hu J, Li X, Che L, Singh A, Yoon A, Chan G, Kelley RK, Swaney DL, Zhang W, Bandyopadhyay S, Theis FJ, Eckhardt M, Chen X, Shokat KM, Ideker T, Krogan NJ, Gordan JD. HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research. 2024. PMID: 39652575
Reddy NR, Maachi H, Xiao Y, Simic MS, Yu W, Tonai Y, Cabanillas DA, Serrano-Wu E, Pauerstein PT, Tamaki W, Allen GM, Parent AV, Hebrok M, Lim WA. Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science (New York, N.Y.). 2024. PMID: 39636990
Ramasamy K, Vij R, Kuter D, Cella D, Durie BGM, Abonour R, Rifkin RM, Ailawadhi S, Lee HC, Cowan AJ, Ho C, Dhanasiri S, Fish S, Yu E, Dhamane AD, Fang J, Marshall TS, Samuel A, Liu L, Katz J, Gu T, Jagannath S. Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody. Volume 25 of Issue 5 Clinical lymphoma, myeloma & leukemia. 2024. PMID: 39799046
Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'loughlin T, Kuzuoglu-Ozturk D, Hua JT, Badura ML, Wilkinson S, Trostel SY, Bergman AM, Ruggero D, Drake CG, Sowalsky AG, Fong L, Cooperberg MR, Zwart W, Guan X, Ashworth A, Xia Z, Quigley DA, Gilbert LA, Feng FY, Moran AE. Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer. Cancer discovery. 2024. PMID: 39652470
Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'loughlin T, Kuzuoglu-Ozturk D, Hua JT, Badura ML, Wilkinson S, Trostel SY, Bergman AM, Ruggero D, Drake CG, Sowalsky AG, Fong L, Cooperberg MR, Zwart W, Guan X, Ashworth A, Xia Z, Quigley DA, Gilbert LA, Feng FY, Moran AE. Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer. Cancer discovery. 2024. PMID: 39652470
Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, Starzinski A, Wolters R, Arias-Badia M, Allaire K, Wu K, Gurunathan V, Valderrábano L, Wei XX, Miller RA, Van Allen EM, Fong L. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2024. PMID: 39633050
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast cancer research and treatment. 2024. PMID: 39625569
Kirk LA, Siropaides CH, Wang J, Chou CL. Effective remediation for advanced practice providers with lowest patient experience: The power of relational resources. Patient education and counseling. 2024. PMID: 39667197
Tamraz B, Venook AP. Reply to: "Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy," "Large-Scale DPD Testing Should Be More Than an Option," and "A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution". JCO oncology practice. 2024. PMID: 39626162
Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clinical genitourinary cancer. 2024. PMID: 39798390
Aldoss I, Roboz GJ, Bassan R, Boissel N, DeAngelo DJ, Fleming S, Gökbuget N, Logan AC, Luger SM, Menne T, Park J, Schuh AC, Shah B, Jabbour E. Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia. The Lancet. Haematology. 2024. PMID: 39638543
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet. Oncology. 2024. PMID: 39637900
Aldoss I, Roboz GJ, Bassan R, Boissel N, DeAngelo DJ, Fleming S, Gökbuget N, Logan AC, Luger SM, Menne T, Park J, Schuh AC, Shah B, Jabbour E. Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia. The Lancet. Haematology. 2024. PMID: 39638543
Sanft T, Day AT, Goldman M, Ansbaugh S, Armenian S, Baker KS, Ballinger TJ, Demark-Wahnefried W, Fairman NP, Feliciano J, Flores TF, Friedman DL, Gabel N, Hill-Kayser C, Koura D, Lee K, Lee N, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, Overholser L, Patel C, Peterson L, Pirl W, Porpiglia A, Schapira L, Schwartz A, Smith S, Tevaarwerk A, Von Ah D, Wake R, Yang E, Zee P, McMillian N, Freedman-Cass D. NCCN Guidelines® Insights: Survivorship, Version 2.2024. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39689426
Woods B, Kearns B, Schmitt L, Jankovic D, Rothery C, Harnan S, Hamilton J, Scope A, Ren S, Bojke L, Wilcox M, Hope W, Leonard C, Howard P, Jenkins D, Ashworth A, Bentley A, Sculpher M. Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. Applied health economics and health policy. 2024. PMID: 39616299